Antihypertensive Drugs Market (Therapy Type: Diuretics, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blockers, Beta-blockers, Vasodilators, Calcium Channel Blockers, Renin Inhibitors, Alpha-blockers, and Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Antihypertensive Drugs market size was estimated at USD 30.8 billion in 2021 and is expected to surpass around USD 41 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 3.45% during the forecast period 2022 to 2030.

Overview of Antihypertensive Drugs Market

Antihypertensive medications are used to treat high blood pressure. Different types of antihypertensive drugs are available in the market. These help lower blood pressure. Some remove excess fluid and salt from the body, while others help relax and widen blood vessels or slow the heart rate. A person could respond better and experience fewer side effects to one drug than to another. Some patients require more than one antihypertensive agent to lower blood pressure.

Hypertension is a preventable risk factor for atherosclerotic disease and ischemic heart disease. A number of patients maintain suboptimal blood pressure control despite the availability of modern and effective antihypertensive drugs. Most hypertensive patients require a combination of antihypertensive agents to achieve treatment goals. Under combination therapy, another class of blood pressure medication is added to the first drug to increase its effectiveness. The antihypertensive drugs market has reasonably high unmet demand, which indicates the lack of effective products. This presents significant opportunities for new entrants to capitalize on the unmet needs, largely due to poor patient compliance with products currently available in the market.

Trends in antihypertensive medication in stroke survivors could provide important insights into gaps in secondary prevention that can guide improved interventions in the future. Healthcare companies are increasing R&D in the field of genomics and resistant hypertension treatment to gain a competitive edge over other market players.

Report Scope of the Antihypertensive Drugs Market

 Launch of New Disease-modifying Therapies to Drive Global Antihypertensive Drugs Market

Innovative antihypertensive drugs and drug therapies are expected to offer favorable outcomes, as these effectively target disease progression. The current scenario in the global antihypertensive drugs market is expected to change due to the launch of new therapies for diseases such as angiotensin II receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, and calcium channel blockers (CCB) during the forecast period.

Currently, physicians prescribe fewer diuretics and beta-blockers, common first-line agents for hypertension, and more ACE and CHF inhibitors. ACE inhibitors reduce mortality and morbidity in cardiovascular patients; however, this is not true for CCBs. If control is not available on beta-blockers, diuretics, or ACE inhibitors, short-acting CHFs should be avoided and alternatives should be considered. Unlike ACE inhibitors, ARBs do not cause cough. Therefore, launch of innovative drug/therapeutic molecules with disease-modifying properties and improved efficacy and safety is expected to drive the global antihypertensive drugs market in the next few years.

Promising Products in Pipeline to Boost Demand for Antihypertensive Drugs

Treatments for hypertension are relatively potent. Several drugs are being studied in clinical trials, including those with disease-modifying properties, better safety, and effectiveness, which can reduce disease progression significantly.

Launch of new products with improved efficiency and safety is expected to drive the market. Bayer's candesartan cilexetil/nifedipine (phase III), Boryung Pharmaceuticals' fimasartan/amlodipine (phase III), and Takeda Pharmaceuticals' diuretic azilsartan/amlodipine/hydrochlorothiazide (phase III) are some of the drugs under development.

Companies Establish Stable Revenue Streams by Augmenting Production of Angiotensin Receptor Blockers

In terms of therapy type, the global antihypertensive drugs market has been classified into diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, vasodilators, calcium channel blockers, renin inhibitors, alpha-blockers, and others. The angiotensin receptor blockers segment is projected to dominate the global market during the forecast period. The segment is expected to grow at a high CAGR from 2021 to 2030. Angiotensin II receptor blockers (ARBs) have a similar effect to ACE inhibitors, another type of blood pressure drug, but work on a different mechanism.

High Salt Intake to Propel Demand for Antihypertensive Drugs for Primary Hypertension Management

Based on type, the global antihypertensive drugs market has been bifurcated into primary hypertension and secondary hypertension. The primary hypertension segment is projected to dominate the global market during the forecast period. The segment is anticipated to grow at a high CAGR from 2022 to 2030. Hypertension has become a global health concern over the last decade. In the developed world, salt intake is generally above the recommended quantity among children. Similar trend exists in the developing world. Positive sodium balance is needed for growth in the first year of life; however, high salt intake could have harmful cardiovascular consequences.

Increase in Geriatric Population with Comorbidities Driving Need for Combination Therapy

In terms of medication, the global antihypertensive drugs market has been segregated into monotherapy, combination therapy, and fixed dose combinations. The combination therapy segment is projected to dominate the market, with significant revenue share by 2030. The segment is anticipated to advance at a high CAGR from 2022 to 2030. Rise in geriatric population with comorbid conditions such as congenital heart disease; and focus on combination therapies are driving the combination therapy segment. Thus, manufacturers are increasing the production of combination antihypertensive drugs to meet the needs of elderly patients with comorbidities.

Broad Medicine Portfolio to Boost Hospital Pharmacies Segment

Based on distribution channel, the global antihypertensive drugs market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment dominated the global market in 2021. Hospital pharmacies usually stock a wide range of medicines, including specialized and investigational medications. Hospital pharmacies are increasing the availability of hypertension management devices to broaden their income sources.

Regional Outlook of Global Antihypertensive Drugs Market

North America dominated the global antihypertensive drugs market in 2021. The market in the region is projected to grow at a high CAGR from 2022 to 2030. North America is anticipated to sustain its market share during the forecast period. High adoption of antihypertensive drugs in the U.S., increase in the number of approvals for new drugs by the U.S. FDA, and rise in percentage of people suffering from cardiovascular diseases in the U.S. and Canada contribute to North America's significant market share.

The market in Asia Pacific region is expected to grow at a high CAGR during the forecast period, owing to the large patient pool, increase in incidence of heart diseases, aging population, and high demand and export of drugs to Europe and North America.

Analysis of Key Players in Antihypertensive Drugs Market

The global antihypertensive drugs market is consolidated, with a small number of leading players accounting for major share. Large numbers of companies are investing in research & development activities. Diversification of product portfolios and mergers & acquisitions are important strategies adopted by key players. Pfizer, Inc., Sanofi S.A, Novartis AG, Boehringer Ingelheim GmbH, Actelion Ltd., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited are the prominent players operating in the global market.

Key Developments in Global Antihypertensive Drugs Market

• In April 2021, Radnor Biopharma developed a hormone-targeting treatment for hypertension
• In 2018, CFDA provided a new clinical approval process for a company to proceed with a clinical trial if the Center for Drug Evaluation Act has no comments on the application within a given period of time
• In July 2018, Daiichi Sankyo Company Limited's antihypertensive drug Sieweika (olmesartan amlodipine tablet) was officially approved in China

Some of the prominent players in the Antihypertensive Drugs Market include:

• Pfizer, Inc.
• Sanofi S.A
• Novartis AG
• Boehringer Ingelheim GmbH
• Actelion Ltd.
• F. Hoffmann-La Roche Ltd.
• Bayer AG
• Daiichi Sankyo Company, Limited
• Takeda Pharmaceutical Company Limited

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Antihypertensive Drugs market

• Therapy Type
• Diuretics
• Angiotensin Converting Enzyme Inhibitors
• Angiotensin Receptor Blockers
• Beta-blockers
• Vasodilators
• Calcium Channel Blockers
• Renin Inhibitors
• Alpha-blockers
• Others
• Type
• Primary Hypertension
• Secondary Hypertension
• Medication Type
• Monotherapy
• Combination Therapy
• Fixed Dose Combinations
• Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Antihypertensive Drugs industry analysis from 2022 to 2030 to identify the prevailing Antihypertensive Drugs industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Antihypertensive Drugs industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Antihypertensive Drugs industry trends, key players, market segments, application areas, and market growth strategies.